bioRxivImmunology
Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes
J. Ahmad, J. Jiang, L. F. Boyd, K. Natarajan, D. H. Margulies
Abstract
The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demands unprecedented attention. We report four X-ray crystal structures of three synthetic nanobodies (sybodies) (Sb16, Sb45 and Sb68) bind to the receptor-binding domain (RBD) of SARS-CoV-2: binary complexes of Sb16-RBD and Sb45-RBD; a ternary complex of Sb45-RBD-Sb68; and Sb16 unliganded. Sb16 and Sb45 bind the RBD at the ACE2 interface, positioning their CDR2 and CDR3 loops diametrically. Sb16 reveals a large CDR2 shift when binding the RBD. Sb68 interacts peripherally at the ACE2 interface; steric clashes with glycans explain its mechanism of viral neutralization. Superposing these structures onto trimeric spike (S) protein models indicates these sybodies bind conformations of the mature S protein differently, which may aid therapeutic design. One Sentence SummaryX-ray structures of synthetic nanobodies complexed with the receptor-binding domain of the spike protein of SARS-CoV-2 reveal details of CDR loop interactions in recognition of distinct epitopic sites.
- organism: virus
- assay: structural biology
- research focus: protein structure prediction
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Sybodies targeting the SARS-CoV-2 receptor-binding domain
J. D. Walter, C. A. J. Hutter, … M. A. Seeger·bioRxiv·Apr 16, 2020
- Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
T. F. Custodio, H. Das, … C. Löw·bioRxiv·Jun 23, 2020
- Binding mechanism of neutralizing Nanobodies targeting SARS-CoV-2 Spike Glycoprotein
M. Golcuk, A. Hacisuleyman, … M. Gur·bioRxiv·Apr 23, 2021
- A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection
- Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
- An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation